Omni-Protech Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 4.50 M
as on 16-11-2024
- Company Age 31 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 31.65 Cr
as on 16-11-2024
- Satisfied Charges ₹ 11.20 Cr
as on 16-11-2024
- Revenue -17.38%
(FY 2023)
- Profit -43.62%
(FY 2023)
- Ebitda -48.43%
(FY 2023)
- Net Worth 9.12%
(FY 2023)
- Total Assets -6.64%
(FY 2023)
About Omni-Protech Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.50 M.
The company currently has active open charges totaling ₹31.65 Cr. The company has closed loans amounting to ₹11.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Brijmohan Sharma, Bipin Katdare, and Atharva Sharma serve as directors at the Company.
- CIN/LLPIN
U24239PN1993PTC071120
- Company No.
071120
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Mar 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Omni-Protech Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Brijmohan Sharma  | Director | 20-Jul-2003 | Current |
| Bipin Katdare | Whole-Time Director | 30-Dec-2008 | Current |
| Atharva Sharma | Director | 09-Jun-2021 | Current |
Financial Performance of Omni-Protech Drugs.
Omni-Protech Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 17.38% decrease. The company also saw a substantial fall in profitability, with a 43.62% decrease in profit. The company's net worth moved up by a moderate rise of 9.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Omni-Protech Drugs?
In 2023, Omni-Protech Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 04 Jun 2024 | ₹20.15 Cr | Open |
Hdfc Bank Limited Creation Date: 23 Feb 2024 | ₹2.00 Cr | Open |
Bnp Paribas Creation Date: 14 Aug 1997 | ₹9.50 Cr | Open |
How Many Employees Work at Omni-Protech Drugs?
Omni-Protech Drugs has a workforce of 84 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omni-Protech Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omni-Protech Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
